216 related articles for article (PubMed ID: 9933447)
1. Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.
Vĕtvicka V; Hanikýrová M; Vĕtvicková J; Ross GD
Clin Exp Immunol; 1999 Feb; 115(2):229-35. PubMed ID: 9933447
[TBL] [Abstract][Full Text] [Related]
2. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.
Vetvicka V; Thornton BP; Ross GD
J Clin Invest; 1996 Jul; 98(1):50-61. PubMed ID: 8690804
[TBL] [Abstract][Full Text] [Related]
3. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells.
Xia Y; Vetvicka V; Yan J; Hanikýrová M; Mayadas T; Ross GD
J Immunol; 1999 Feb; 162(4):2281-90. PubMed ID: 9973505
[TBL] [Abstract][Full Text] [Related]
4. Selective reduction of natural killer cells and T cells expressing inhibitory receptors for MHC class I in the livers of patients with hepatic malignancy.
Norris S; Doherty DG; Curry M; McEntee G; Traynor O; Hegarty JE; O'Farrelly C
Cancer Immunol Immunother; 2003 Jan; 52(1):53-8. PubMed ID: 12536240
[TBL] [Abstract][Full Text] [Related]
5. Requirement of leukocytic cell adhesion molecules (CD11a-c/CD18) in the enhanced NK lysis of iC3b-opsonized targets.
Ramos OF; Patarroyo M; Yefenof E; Klein E
J Immunol; 1989 Jun; 142(11):4100-4. PubMed ID: 2565929
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.
Mingari MC; Vitale C; Cantoni C; Bellomo R; Ponte M; Schiavetti F; Bertone S; Moretta A; Moretta L
Eur J Immunol; 1997 Jun; 27(6):1374-80. PubMed ID: 9209487
[TBL] [Abstract][Full Text] [Related]
7. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18).
Vetvicka V; Thornton BP; Wieman TJ; Ross GD
J Immunol; 1997 Jul; 159(2):599-605. PubMed ID: 9218574
[TBL] [Abstract][Full Text] [Related]
8. Expression of p58.2 or CD94/NKG2A inhibitory receptors in an NK-like cell line, YTINDY, leads to HLA Class I-mediated inhibition of cytotoxicity in the p58.2- but not the CD94/NKG2A-expressing transfectant.
Lin Chua H; Brahmi Z
Cell Immunol; 2002 Sep; 219(1):57-70. PubMed ID: 12473268
[TBL] [Abstract][Full Text] [Related]
9. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E.
Valés-Gómez M; Reyburn HT; Erskine RA; López-Botet M; Strominger JL
EMBO J; 1999 Aug; 18(15):4250-60. PubMed ID: 10428963
[TBL] [Abstract][Full Text] [Related]
10. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.
Braud VM; Allan DS; O'Callaghan CA; Söderström K; D'Andrea A; Ogg GS; Lazetic S; Young NT; Bell JI; Phillips JH; Lanier LL; McMichael AJ
Nature; 1998 Feb; 391(6669):795-9. PubMed ID: 9486650
[TBL] [Abstract][Full Text] [Related]
11. The CD94/NKG2 C-type lectin receptor complex: involvement in NK cell-mediated recognition of HLA class I molecules.
López-Botet M; Carretero M; Pérez-Villar J; Bellón T; Llano M; Navarro F
Immunol Res; 1997; 16(2):175-85. PubMed ID: 9212363
[TBL] [Abstract][Full Text] [Related]
12. The CD94/NKG2-A inhibitory receptor complex is involved in natural killer cell-mediated recognition of cells expressing HLA-G1.
Pérez-Villar JJ; Melero I; Navarro F; Carretero M; Bellón T; Llano M; Colonna M; Geraghty DE; López-Botet M
J Immunol; 1997 Jun; 158(12):5736-43. PubMed ID: 9190923
[TBL] [Abstract][Full Text] [Related]
13. Specific engagement of the CD94/NKG2-A killer inhibitory receptor by the HLA-E class Ib molecule induces SHP-1 phosphatase recruitment to tyrosine-phosphorylated NKG2-A: evidence for receptor function in heterologous transfectants.
Carretero M; Palmieri G; Llano M; Tullio V; Santoni A; Geraghty DE; López-Botet M
Eur J Immunol; 1998 Apr; 28(4):1280-91. PubMed ID: 9565368
[TBL] [Abstract][Full Text] [Related]
14. Orderly and nonstochastic acquisition of CD94/NKG2 receptors by developing NK cells derived from embryonic stem cells in vitro.
Lian RH; Maeda M; Lohwasser S; Delcommenne M; Nakano T; Vance RE; Raulet DH; Takei F
J Immunol; 2002 May; 168(10):4980-7. PubMed ID: 11994449
[TBL] [Abstract][Full Text] [Related]
15. Direct binding of purified HLA class I antigens by soluble NKG2/CD94 C-type lectins from natural killer cells.
Ding Y; Sumitran S; Holgersson J
Scand J Immunol; 1999 May; 49(5):459-65. PubMed ID: 10320637
[TBL] [Abstract][Full Text] [Related]
16. CD94/NKG2-A inhibitory complex blocks CD16-triggered Syk and extracellular regulated kinase activation, leading to cytotoxic function of human NK cells.
Palmieri G; Tullio V; Zingoni A; Piccoli M; Frati L; Lopez-Botet M; Santoni A
J Immunol; 1999 Jun; 162(12):7181-8. PubMed ID: 10358164
[TBL] [Abstract][Full Text] [Related]
17. HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells.
King A; Allan DS; Bowen M; Powis SJ; Joseph S; Verma S; Hiby SE; McMichael AJ; Loke YW; Braud VM
Eur J Immunol; 2000 Jun; 30(6):1623-31. PubMed ID: 10898498
[TBL] [Abstract][Full Text] [Related]
18. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).
Yan J; Vetvicka V; Xia Y; Coxon A; Carroll MC; Mayadas TN; Ross GD
J Immunol; 1999 Sep; 163(6):3045-52. PubMed ID: 10477568
[TBL] [Abstract][Full Text] [Related]
19. Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells.
Klein E; Di Renzo L; Yefenof E
Mol Immunol; 1990 Dec; 27(12):1343-7. PubMed ID: 1980339
[TBL] [Abstract][Full Text] [Related]
20. CR3 (CD11b/CD18) expressed by cytotoxic T cells and natural killer cells is upregulated in a manner similar to neutrophil CR3 following stimulation with various activating agents.
Muto S; Vĕtvicka V; Ross GD
J Clin Immunol; 1993 May; 13(3):175-84. PubMed ID: 8100571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
